Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Tauopathy is one of the pathological features of Alzheimer's disease and related dementias (ADRD).
Why it matters
This review describes how vascular risk factors and blood vessel dysfunction interact with tau pathology in Alzheimer's disease and related dementias, suggesting vascular health as a possible target for combination therapy. It is a review of mechanisms, not proof that any treatment works.
-
APP/PS1 mice at 6 months were randomly allocated to two dietary groups: one receiving ad libitum (AL) feeding and the other undergoing IF for 1 month.
Why it matters
In APP/PS1 mice, one month of intermittent fasting improved cognition and reduced amyloid deposition, associated with less lipid droplet accumulation in microglia. This is a mouse study, so it does not prove that intermittent fasting prevents or treats Alzheimer's disease in people.
-
Neurodegenerative diseases are currently among the most devastating diseases with no effective disease-modifying drugs in the market, with Alzheimer's disease (AD) being the most prevalent.
Why it matters
This review examines whether drugs acting on adrenergic receptors might benefit Alzheimer's disease and other dementias. It states that results so far remain inconclusive because of the heterogeneity of the drug classes studied, so no treatment or prevention benefit is established.
-
These models demonstrated high diagnostic efficacy in distinguishing diseased samples from healthy donors as well as distinguishing AD and DLB cases.
Why it matters
Models based on peripheral single-cell immune characteristics distinguished diseased samples from healthy donors and distinguished Alzheimer's disease from dementia with Lewy bodies, with Alzheimer's disease showing a decrease in total T cells. These findings are proposed as potential diagnostic biomarkers and do not address treating, curing or preventing Alzheimer's disease.
-
Alzheimer?s disease (AD) is a neurodegenerative disorder with a strong genetic component.
Why it matters
In a case-control study of 98 patients and 156 controls in northeast Algeria, the ABCA7 rs3764650 and PSEN1 rs165932 variants were associated with higher Alzheimer's disease risk, particularly in females and late-onset cases. These findings suggest these variants may serve as genetic markers of disease risk, but they do not demonstrate a treatment or cure.
-
The analyses of the community‐based U.S. POINTER indicate that AA/B individuals present differences in AD and related dementia biomarker values. nHW had higher fully adjusted cognitive scores.
Why it matters
In this study of participants in a lifestyle intervention trial, African American/Black participants had different levels of some Alzheimer's-related biomarkers and cognitive measures compared with non-Hispanic White participants. It does not test whether the lifestyle intervention works, and the authors say the results indicate a need for more research on these differences.
-
There is a consistent difference between Appalachian and non‐Appalachian counties, with Appalachian counties having relatively higher ADRD prevalence (in the range of 2.0‐3.0% times higher) than non‐Appalachian counties.
Why it matters
This study examined county-level prevalence of Alzheimer's disease and related dementias in Central Appalachia and whether geographic variation was explained by sociodemographic factors or access to care. The abstract does not report the final results of these analyses.
-
P‐tau217/Aβ42 had the highest performance to discriminate Aβ+ from Aβ‐ (Table 1A,1B; all AUC≥0.90), and p‐tau217 showed excellent accuracy in ADNI sample (0.96; Table 1B).
Why it matters
This study compared plasma p-tau217 and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease. It found that p-tau217/Aβ42 had the highest performance to discriminate Aβ+ from Aβ-, and that Black individuals had significantly higher Aβ42 while no difference was observed for p-tau217 or p-tau217/Aβ42.
-
Alzheimer's disease currently has no cure and is usually detected too late for interventions to be effective.
Why it matters
In cognitively normal people, this study mapped how age and APOE gene variation relate to long-range brain connections, finding that certain connections in the occipital cortex and cerebellum declined faster depending on genotype. These are possible early markers of neurodegeneration, but the work does not test any treatment or prevention.
-
38/100
Investigating new drugs or formulations that target Alzheimer disease (AD) is critical for advancing therapeutic interventions.
Why it matters
In a rat model of Alzheimer disease, nanoencapsulated curcumin reversed memory deficits and reduced measures of oxidative stress and neuroinflammation. This is animal research and does not establish that this formulation treats or prevents Alzheimer disease in people.
-
A person affected by Alzheimer's disease (AD) gradually loses the ability to perform activities of daily living and becomes dependent on caregivers, thereby having a negative impact on the caregivers' quality of life.
Why it matters
This is a protocol for a trial of a mindfulness program for caregivers of people with Alzheimer's disease. No results are reported, and it focuses on caregiver outcomes rather than treating or preventing the disease.
-
Clinical trial registration www.
Why it matters
In 60 anemic older patients with mild cognitive dysfunction, combined low-level laser therapy and moderate aerobic exercise improved cognitive and quality-of-life scores more than exercise alone over 12 weeks. This small trial addresses symptom improvement in a specific group, not curing or preventing Alzheimer's disease.
-
Alzheimer's disease (AD) is a prevalently found tauopathy characterized by memory loss and cognitive insufficiency.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by an asymptomatic period of amyloid-β (Aβ) deposition as insoluble extracellular plaque, intracellular tau aggregation, neuronal and synaptic loss, and subsequent cognitive dysfunction and dementia.
-
Alzheimer's disease (AD) is the most common form of dementia worldwide. β-amyloid peptide (Aβ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD, but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored.
-
Alzheimer's disease (AD) is a devastating and irreversible cognitive impairment and the most common type of dementia.
-
It is increasingly accepted that early cognitive impairment in Alzheimer's disease results in considerable part from synaptic dysfunction caused by the accumulation of a range of oligomeric assemblies of amyloid β-protein (Aβ).
-
Alzheimer's (or Alzheimer) disease (AD) is the most prevalent subset of dementia, affecting elderly populations worldwide.
-
Diabetes mellitus (DM) is a gradually rising metabolic disease which is currently affecting millions of people worldwide.
-
This paper summarizes the available evidence of pro- and anti-inflammatory activity of some dietary components including fatty acids, vitamins, flavonoids, polyphenols, probiotics and d-AGE, and their potential for AD prevention and treatment.
-
Social determinants of health, such as neighborhood disadvantage, have been linked to an increased risk of clinical dementia syndrome; however, their association with neuropathologically confirmed Alzheimer's disease (AD) remains unknown.
Why it matters
This study examined whether neighborhood disadvantage is linked to neuropathologically confirmed Alzheimer's disease in 434 brain bank participants. It used the Area Deprivation Index, a measure incorporating poverty, education, housing and employment indicators, to compare those in the most disadvantaged 20% of neighborhoods to those in the least disadvantaged 80%.
-
Alzheimer's disease (AD) is an irreversible, progressive disease that slowly destroys cognitive function, such as thinking, remembering, and reasoning, to a level that one cannot carry out a daily living.
-
Melatonin, a pineal gland synthesized neurohormone is known as a multifunctioning pleiotropic agent which has a wide range of neuroprotective role in manifold age-related neurodegenerative disorders especially Alzheimer's diseases (AD).
-
Alzheimer's disease (AD) is the commonest neurodegenerative disease and the most frequent cause of dementia.
-
Alzheimer's disease (AD) is characterized by the presence of amyloid-β (Aβ), oxidative damage and neuronal degeneration, which, together with other pathological events, promote progressive memory loss and cognitive decline.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
- P-TAU217 COMO BIOMARCADOR SANGUÍNEO NO DIAGNÓSTICO PRECOCE DA DOENÇA DE ALZHEIMER: UMA REVISÃO DA LITERATURA
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
- Influence of leisure activity on the incidence of Alzheimer's disease
- Body mass index in midlife and risk of Alzheimer disease and vascular dementia
- Causality between Alzheimer disease and delirium: A two-sample Mendelian randomization study and gene colocalization analyses
- [Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]
- Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis
- Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease
- Longitudinal Association of a Polygenic Risk Score for Plasma T-Tau With Incident Alzheimer Dementia and Mild Cognitive Impairment